Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1141 ARTÍCULOS , VIENDO DEL 841 AL 855

Strength and weaknesses of cerebrospinal fluid biomarkers in Alzheimer's disease and possible detection of overlaps with frailty process

Stefani A, Olivola E, Stampanoni Bassi M, Pisani V, Imbriani P, Pisani A, Pierantozzi M.

CNS Neurol Disord Drug Targets. 2013 Jun;12(4):538-46. doi: 10.2174/1871527311312040016.

Previously not recognized deletion in presenilin-1 (p.Leu174del.) in a patient with early-onset familial Alzheimer's disease

Tiedt HO, Lueschow A, Winter P, Müller U.

Neurosci Lett. 2013 Jun 7;544:115-8. doi: 10.1016/j.neulet.2013.03.056. Epub 2013 Apr 10.

[New risk genes for Alzheimer's disease--biomarkers predicting the disease?]

Hiltunen M, Haapasalo A, Soininen H.

Duodecim. 2013;129(6):583-8.

Alzheimer's disease biomarkers: correspondence between human studies and animal models

Sabbagh JJ, Kinney JW, Cummings JL.

Neurobiol Dis. 2013 Aug;56:116-30. doi: 10.1016/j.nbd.2013.04.010. Epub 2013 Apr 28.

Innovative potential treatment strategies for schizophrenia and biomarkers for Alzheimer's disease

Schmitt A, Falkai P.

Eur Arch Psychiatry Clin Neurosci. 2013 Jun;263(4):271-2. doi: 10.1007/s00406-013-0409-0.

Cerebrospinal fluid levels of phosphorylated tau and Aβ1-38/Aβ1-40/Aβ1-42 in Alzheimer's disease with PS1 mutations

Ikeda M, Yonemura K, Kakuda S, Tashiro Y, Fujita Y, Takai E, Hashimoto Y, Makioka K, Furuta N, Ishiguro K, Maruki R, Yoshida J, Miyaguchi O, Tsukie T, Kuwano R, Yamazaki T, Yamaguchi H, Amari M, Takatama M, Harigaya Y, Okamoto K.

Amyloid. 2013 Jun;20(2):107-12. doi: 10.3109/13506129.2013.790810. Epub 2013 May 2.

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease

Blennow K, Zetterberg H.

Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1.

Clinical trials in predementia stages of Alzheimer disease

Pillai JA, Cummings JL.

Med Clin North Am. 2013 May;97(3):439-57. doi: 10.1016/j.mcna.2013.01.002. Epub 2013 Feb 22.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1.

Application of the National Institute on Aging-Alzheimer's Association AD criteria to ADNI

Lowe VJ, Peller PJ, Weigand SD, Montoya Quintero C, Tosakulwong N, Vemuri P, Senjem ML, Jordan L, Jack CR Jr, Knopman D, Petersen RC.

Neurology. 2013 Jun 4;80(23):2130-7. doi: 10.1212/WNL.0b013e318295d6cf. Epub 2013 May 3.

Single-domain amnestic mild cognitive impairment identified by cluster analysis predicts Alzheimer's disease in the european prospective DESCRIPA study

Damian M, Hausner L, Jekel K, Richter M, Froelich L, Almkvist O, Boada M, Bullock R, De Deyn PP, Frisoni GB, Hampel H, Jones RW, Kehoe P, Lenoir H, Minthon L, Olde Rikkert MG, Rodriguez G, Scheltens P, Soininen H, Spiru L, Touchon J, Tsolaki M, Vellas B, Verhey FR, Winblad B, Wahlund LO, Wilcock G, Visser PJ.

Dement Geriatr Cogn Disord. 2013;36(1-2):1-19. doi: 10.1159/000348354. Epub 2013 May 3.

Mild cognitive impairment due to Alzheimer disease in the community

Petersen RC, Aisen P, Boeve BF, Geda YE, Ivnik RJ, Knopman DS, Mielke M, Pankratz VS, Roberts R, Rocca WA, Weigand S, Weiner M, Wiste H, Jack CR Jr.

Ann Neurol. 2013 Aug;74(2):199-208. doi: 10.1002/ana.23931.

APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer's disease

Reinvang I, Espeseth T, Westlye LT.

Neurosci Biobehav Rev. 2013 Sep;37(8):1322-35. doi: 10.1016/j.neubiorev.2013.05.006. Epub 2013 May 20.

Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly

Randall C, Mosconi L, de Leon M, Glodzik L.

Front Biosci (Landmark Ed). 2013 Jun 1;18(3):1150-73. doi: 10.2741/4170.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias